Journal ArticleAm Heart J · October 2024
BACKGROUND: Our objective was to determine the number of major cardiovascular events (MACE, nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and deaths from any cause that could be prevented across varying nationwide uptake of sema ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · August 20, 2024
BACKGROUND: Emerging data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve kidney outcomes for people with type 2 diabetes (T2D). Direct comparisons of the kidney and cardiovascular effectiveness of GLP-1 RA with sodium-glucose co ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Heart J · August 2024
BACKGROUND: Patients with obesity and advanced heart failure requiring left ventricular assist device (LVAD) support are more likely to experience LVAD complications and may be disproportionately Black and/or female when compared to patients without obesit ...
Full textLink to itemCite
Journal ArticleCirculation · July 16, 2024
BACKGROUND: Results from the COORDINATE-Diabetes trial (Coordinating Cardiology Clinics Randomized Trial of Interventions to Improve Outcomes - Diabetes) demonstrated that a multifaceted, clinic-based intervention increased prescription of evidence-based m ...
Full textLink to itemCite
Journal ArticleJ Womens Health (Larchmt) · July 2024
Background: Pregnancy-related cardiovascular (CV) conditions, including hypertensive disorders of pregnancy (HDP) and gestational diabetes (GDM), are associated with increased long-term CV risk. Methods: This retrospective cohort study defined the prevalen ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · June 15, 2024
Placebo-controlled trials of sodium-glucose co-transporter-2 inhibitors demonstrate kidney and cardiovascular benefits for patients with type 2 diabetes and chronic kidney disease (CKD). We used real-world data to compare the kidney and cardiovascular effe ...
Full textOpen AccessLink to itemCite
Journal ArticleJAMA Netw Open · June 3, 2024
IMPORTANCE: Chronic kidney disease (CKD) is an often-asymptomatic complication of type 2 diabetes (T2D) that requires annual screening to diagnose. Patient-level factors linked to inadequate screening and treatment can inform implementation strategies to f ...
Full textOpen AccessLink to itemCite
Journal ArticleNat Rev Cardiol · June 2024
Non-adherence to medication is a global health problem with far-reaching individual-level and population-level consequences but remains unappreciated and under-addressed in the clinical setting. With increasing comorbidity and polypharmacy as well as an ag ...
Full textOpen AccessLink to itemCite
Journal ArticleAm J Prev Cardiol · June 2024
OBJECTIVE: Obesity is associated with a higher risk of cardiovascular disease. Understanding the associations between comprehensive health parameters and body mass index (BMI) may lead to targeted prevention efforts. METHODS: Project Baseline Health Study ...
Full textLink to itemCite
Journal ArticleCurr Heart Fail Rep · June 2024
PURPOSE OF REVIEW: To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure. RECENT FINDINGS: Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fracti ...
Full textLink to itemCite
Journal ArticleAm J Prev Cardiol · June 2024
OBJECTIVES: To determine the relationship between lipoprotein particle size/number with hepatic steatosis (HS), given its association with traditional lipoproteins and coronary atherosclerosis. METHODS: Individuals with available CT data and blood samples ...
Full textLink to itemCite
Journal ArticleMed Clin North Am · May 2024
Patients with type 2 diabetes and/or obesity and established cardiovascular disease are at increased risk for recurrent cardiovascular events. The indications of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibi ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2024
AIMS: Type 2 diabetes (T2D) is a risk factor for cardiovascular and non-cardiovascular mortality. However, global distribution of cause-specific deaths in T2D is poorly understood. We characterized cause-specific deaths by geographic region among individua ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2024
The global pharmaceutical industry portfolio is skewed towards cancer and rare diseases due to more predictable development pathways and financial incentives. In contrast, drug development for major chronic health conditions that are responsible for a larg ...
Full textLink to itemCite
Journal ArticleCurr Cardiol Rep · March 2024
PURPOSE OF REVIEW: Obesity is associated with cardiovascular (CV) conditions, including but not limited to atherosclerotic disease, heart failure, and atrial fibrillation. Despite this, the impact of intentional weight loss on CV outcomes for persons with ...
Full textLink to itemCite
Journal ArticleJ Card Fail · February 2024
Despite recent advances in the use of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF), achievement of target GDMT use and up-titration to goal dosages continue to be modest. In recent years, ...
Full textOpen AccessLink to itemCite
Journal ArticleSurg Obes Relat Dis · January 2024
BACKGROUND: Patients with metabolic syndrome (MetS) are at increased risk of developing cardiovascular disease along with other adverse events after bariatric surgery. OBJECTIVES: The incidence of short-term major adverse cardiovascular events (MACE) in pa ...
Full textLink to itemCite
Journal ArticleJACC Heart Fail · January 2024
Obesity is associated with incident heart failure (HF), independent of other cardiovascular risk factors. Despite rising rates of both obesity and incident HF, the associations remain poorly understood between: 1) obesity and HF outcomes; and 2) weight los ...
Full textLink to itemCite
Journal ArticleNature Reviews Cardiology · January 1, 2024
Multiple professional societies recommend the Mediterranean and/or Dietary Approaches to Stop Hypertension dietary patterns in their cardiovascular disease prevention guidelines because these diets can improve cardiometabolic health and reduce the risk of ...
Full textCite
Journal ArticleJ Am Coll Cardiol · November 7, 2023
BACKGROUND: Renal denervation (RDN) reduces blood pressure (BP) in patients with uncontrolled hypertension in the absence of antihypertensive medications. OBJECTIVES: This trial assessed the safety and efficacy of RDN in the presence of antihypertensive me ...
Full textLink to itemCite
Journal ArticleAm Heart J · October 2024
BACKGROUND: Our objective was to determine the number of major cardiovascular events (MACE, nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and deaths from any cause that could be prevented across varying nationwide uptake of sema ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · August 20, 2024
BACKGROUND: Emerging data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve kidney outcomes for people with type 2 diabetes (T2D). Direct comparisons of the kidney and cardiovascular effectiveness of GLP-1 RA with sodium-glucose co ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Heart J · August 2024
BACKGROUND: Patients with obesity and advanced heart failure requiring left ventricular assist device (LVAD) support are more likely to experience LVAD complications and may be disproportionately Black and/or female when compared to patients without obesit ...
Full textLink to itemCite
Journal ArticleCirculation · July 16, 2024
BACKGROUND: Results from the COORDINATE-Diabetes trial (Coordinating Cardiology Clinics Randomized Trial of Interventions to Improve Outcomes - Diabetes) demonstrated that a multifaceted, clinic-based intervention increased prescription of evidence-based m ...
Full textLink to itemCite
Journal ArticleJ Womens Health (Larchmt) · July 2024
Background: Pregnancy-related cardiovascular (CV) conditions, including hypertensive disorders of pregnancy (HDP) and gestational diabetes (GDM), are associated with increased long-term CV risk. Methods: This retrospective cohort study defined the prevalen ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · June 15, 2024
Placebo-controlled trials of sodium-glucose co-transporter-2 inhibitors demonstrate kidney and cardiovascular benefits for patients with type 2 diabetes and chronic kidney disease (CKD). We used real-world data to compare the kidney and cardiovascular effe ...
Full textOpen AccessLink to itemCite
Journal ArticleJAMA Netw Open · June 3, 2024
IMPORTANCE: Chronic kidney disease (CKD) is an often-asymptomatic complication of type 2 diabetes (T2D) that requires annual screening to diagnose. Patient-level factors linked to inadequate screening and treatment can inform implementation strategies to f ...
Full textOpen AccessLink to itemCite
Journal ArticleNat Rev Cardiol · June 2024
Non-adherence to medication is a global health problem with far-reaching individual-level and population-level consequences but remains unappreciated and under-addressed in the clinical setting. With increasing comorbidity and polypharmacy as well as an ag ...
Full textOpen AccessLink to itemCite
Journal ArticleAm J Prev Cardiol · June 2024
OBJECTIVE: Obesity is associated with a higher risk of cardiovascular disease. Understanding the associations between comprehensive health parameters and body mass index (BMI) may lead to targeted prevention efforts. METHODS: Project Baseline Health Study ...
Full textLink to itemCite
Journal ArticleCurr Heart Fail Rep · June 2024
PURPOSE OF REVIEW: To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure. RECENT FINDINGS: Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fracti ...
Full textLink to itemCite
Journal ArticleAm J Prev Cardiol · June 2024
OBJECTIVES: To determine the relationship between lipoprotein particle size/number with hepatic steatosis (HS), given its association with traditional lipoproteins and coronary atherosclerosis. METHODS: Individuals with available CT data and blood samples ...
Full textLink to itemCite
Journal ArticleMed Clin North Am · May 2024
Patients with type 2 diabetes and/or obesity and established cardiovascular disease are at increased risk for recurrent cardiovascular events. The indications of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibi ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2024
AIMS: Type 2 diabetes (T2D) is a risk factor for cardiovascular and non-cardiovascular mortality. However, global distribution of cause-specific deaths in T2D is poorly understood. We characterized cause-specific deaths by geographic region among individua ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2024
The global pharmaceutical industry portfolio is skewed towards cancer and rare diseases due to more predictable development pathways and financial incentives. In contrast, drug development for major chronic health conditions that are responsible for a larg ...
Full textLink to itemCite
Journal ArticleCurr Cardiol Rep · March 2024
PURPOSE OF REVIEW: Obesity is associated with cardiovascular (CV) conditions, including but not limited to atherosclerotic disease, heart failure, and atrial fibrillation. Despite this, the impact of intentional weight loss on CV outcomes for persons with ...
Full textLink to itemCite
Journal ArticleJ Card Fail · February 2024
Despite recent advances in the use of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF), achievement of target GDMT use and up-titration to goal dosages continue to be modest. In recent years, ...
Full textOpen AccessLink to itemCite
Journal ArticleSurg Obes Relat Dis · January 2024
BACKGROUND: Patients with metabolic syndrome (MetS) are at increased risk of developing cardiovascular disease along with other adverse events after bariatric surgery. OBJECTIVES: The incidence of short-term major adverse cardiovascular events (MACE) in pa ...
Full textLink to itemCite
Journal ArticleJACC Heart Fail · January 2024
Obesity is associated with incident heart failure (HF), independent of other cardiovascular risk factors. Despite rising rates of both obesity and incident HF, the associations remain poorly understood between: 1) obesity and HF outcomes; and 2) weight los ...
Full textLink to itemCite
Journal ArticleNature Reviews Cardiology · January 1, 2024
Multiple professional societies recommend the Mediterranean and/or Dietary Approaches to Stop Hypertension dietary patterns in their cardiovascular disease prevention guidelines because these diets can improve cardiometabolic health and reduce the risk of ...
Full textCite
Journal ArticleJ Am Coll Cardiol · November 7, 2023
BACKGROUND: Renal denervation (RDN) reduces blood pressure (BP) in patients with uncontrolled hypertension in the absence of antihypertensive medications. OBJECTIVES: This trial assessed the safety and efficacy of RDN in the presence of antihypertensive me ...
Full textLink to itemCite
Journal ArticleCurr Cardiol Rep · November 2023
PURPOSE OF REVIEW: There has been much debate surrounding the use of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), for cardiovascular (CV) risk reduction. RECENT FINDINGS: Recent trials of EPA and DHA have offered conflic ...
Full textLink to itemCite
Journal ArticleEur Radiol · July 2023
OBJECTIVES: To compare the prognostic value of individual CT-derived coronary artery disease (CAD) characteristics across categories of clinical cardiovascular risk. METHODS: The central core laboratory assessed coronary artery calcium (CAC), obstructive C ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · June 6, 2023
Background The interplay between branched-chain amino acid (BCAA) metabolism, an important pathway in adiposity and cardiometabolic disease, and visceral adipose depots such as hepatic steatosis (HS) and epicardial adipose tissue is unknown. We leveraged t ...
Full textLink to itemCite
ConferenceAm J Prev Cardiol · June 2023
OBJECTIVE: Elevated lipoprotein(a) [Lp(a)] is associated with atherosclerotic cardiovascular disease, yet little is known about Lp(a) testing patterns in real-world practice. The objective of this analysis was to determine how Lp(a) testing is used in clin ...
Full textLink to itemCite
Journal ArticleCirc Genom Precis Med · June 2023
BACKGROUND: Epigenetic clocks estimate chronologic age using methylation levels at specific loci. We tested the hypothesis that accelerated epigenetic aging is associated with abnormal values in a range of clinical, imaging, and laboratory characteristics. ...
Full textLink to itemCite
Journal ArticlePrev Med · May 2023
Whether individuals in real-world settings are able to lose weight and improve cardiometabolic risk factors over time is unclear. We aimed to determine the management of and degree of body weight change over 2 years among individuals with overweight or obe ...
Full textLink to itemCite
Journal ArticleJAMA · April 18, 2023
IMPORTANCE: Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk in adults with type 2 diabetes are underused in clinical practice. OBJECTIVE: To assess the effect of a coordinated, multifaceted intervention of assessment, educati ...
Full textLink to itemCite
Journal ArticleJ Am Geriatr Soc · April 2023
BACKGROUND: The contemporary uptake of lipid-lowering therapies (LLT), including more intensive treatment with high-intensity statins and non-statin LLT, among U.S. older adults (≥75 years old) with ASCVD is unknown. METHODS: In this multicenter retrospect ...
Full textLink to itemCite
Journal ArticleAm J Prev Cardiol · March 2023
Cardiovascular disease remains one of the most prominent global health problems and has been demonstrated to disproportionally affect certain communities. Despite an increasing collective effort to improve health inequalities, a multitude of disparities co ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Heart J · February 2023
Several medications that are proven to reduce cardiovascular events exist for individuals with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease, however they are substantially underused in clinical practice. Clinician, patient, an ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · January 1, 2023
Guidelines recommend aggressive low-density lipoprotein cholesterol (LDL-C) lowering in patients with atherosclerotic cardiovascular disease (ASCVD). However, the recommended threshold of LDL-C ≤70 mg/dL is often not achieved. We used data from the Duke Un ...
Full textLink to itemCite
Journal ArticleCurr Cardiol Rep · October 2022
PURPOSE OF REVIEW: Women are less often recognized to have cardiovascular disease (CVD) risk and are underrepresented in randomized trials of lipid-lowering therapy. Here, we summarize non-pharmacologic and pharmacologic strategies for lipid-lowering in wo ...
Full textLink to itemCite
Journal ArticleCurr Cardiol Rep · October 2022
PURPOSE OF REVIEW: Given the increasing burden of cardiovascular disease, we review the literature for earlier initiation of statin therapy at younger ages and lower low-density lipoprotein cholesterol (LDL-C) levels, with the goal of preventing the develo ...
Full textLink to itemCite
Journal ArticleHeart Fail Clin · October 2022
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) improve the risk for heart and kidney failure. However, their effects on major atherosclerotic cardiovascular events (MACE) are less clear. Although outcomes trials of drugs for diabetes were not powered ...
Full textLink to itemCite
Journal ArticleHeart · August 25, 2022
Cardiovascular (CV) risk factors are rising among women of reproductive age. Obesity, hyperlipidaemia, diabetes, and hypertension are associated with adverse pregnancy outcomes and increased CV disease (CVD) risk following pregnancy. Pre-conception counsel ...
Full textLink to itemCite
Journal ArticleCardiovasc Diabetol · July 18, 2022
BACKGROUND: We examined multi-dimensional clinical and laboratory data in participants with normoglycemia, prediabetes, and diabetes to identify characteristics of prediabetes and predictors of progression from prediabetes to diabetes or reversion to no di ...
Full textLink to itemCite
Journal ArticleCurr Hypertens Rep · July 2022
PURPOSE OF REVIEW: To review the data on hypertensive disorders of pregnancy (HDP) and heart failure (HF) risk. RECENT FINDINGS: Hypertensive disorders are the most common medical condition affecting women during pregnancy and are associated with future HF ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · May 10, 2022
Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus. These high-risk patients benefit from aggressive risk factor management, with blood pressure and low-density lipoprotein-cholesterol treatmen ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · May 10, 2022
BACKGROUND: Preventive therapy among patients with established atherosclerotic cardiovascular disease (ASCVD) is generally underused. Whether new guideline recommendations and a focus on implementation have improved the use of high-intensity statins is unk ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · May 2022
BACKGROUND: Patients evaluated for coronary artery disease have a range of symptoms and underlying risk. The relationships between patient-described symptoms, clinician conclusions, and subsequent clinical management and outcomes remain incompletely descri ...
Full textLink to itemCite
Journal ArticleEur Heart J · April 19, 2022
AIMS: Patients with heart failure (HF) have not been shown to benefit from statins. In a post hoc analysis, we evaluated outcomes in ODYSSEY OUTCOMES in patients with vs. without a history of HF randomized to the proprotein convertase subtilisin/kexin type ...
Full textLink to itemCite
Journal ArticleJAMA Netw Open · February 1, 2022
IMPORTANCE: Based on contemporary estimates in the US, evidence-based therapies for cardiovascular risk reduction are generally underused among patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). OBJECTIVE: To determine the us ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Comput Tomogr · 2022
BACKGROUND: Pretest probability (PTP) calculators utilize epidemiological-level findings to provide patient-level risk assessment of obstructive coronary artery disease (CAD). However, their limited accuracies question whether dissimilarities in risk facto ...
Full textLink to itemCite
Journal ArticlePrev Med Rep · December 2021
Data on patterns of weight change among adults with overweight or obesity are minimal. We aimed to examine patterns of weight change and associated hospitalizations in a large health system, and to develop a model to predict 2-year significant weight gain. ...
Full textLink to itemCite
Journal ArticleAtherosclerosis · December 2021
BACKGROUND AND AIMS: Polyvascular disease is an independent predictor of major adverse cardiovascular events (MACE). The relationship between the number of diseased arterial beds and MACE is unknown. How MACE risk changes in individuals with type 2 diabete ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · November 16, 2021
Sodium-glucose cotransporter-2 inhibitor therapy is well suited for initiation during the heart failure hospitalization, owing to clinical benefits that accrue rapidly within days to weeks, a strong safety and tolerability profile, minimal to no effects on ...
Full textLink to itemCite
Journal ArticleJACC Cardiovasc Imaging · November 2021
OBJECTIVES: The purpose of this study was to develop a risk prediction model for patients with nonobstructive CAD. BACKGROUND: Among stable chest pain patients, most cardiovascular (CV) events occur in those with nonobstructive coronary artery disease (CAD ...
Full textLink to itemCite
Journal ArticleDiabet Med · October 2021
AIMS: Although models exist to predict amputation among people with type 2 diabetes with foot ulceration or infection, we aimed to develop a prediction model for a broader range of major adverse limb events (MALE)-including gangrene, revascularization and ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 2021
Cardiovascular (CV) outcome studies of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shifted the paradigm of type 2 diabetes management given their benefits regarding a reduction in major adverse CV events. However, the relationship between GL ...
Full textLink to itemCite
Journal ArticleAm J Med · September 2021
Despite decades of research into risk-reduction strategies, cardiovascular disease and renal disease remain leading causes of morbidity and mortality among patients with type 2 diabetes mellitus. Given the tight clustering of cardiovascular and renal disea ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · August 15, 2021
Lipoprotein (a) [Lp(a)] is associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). As directed therapy for Lp(a) emerges, it is important to understand patterns of Lp(a) testing in routine clinical practice. We set out to characte ...
Full textLink to itemCite
Journal ArticleCirculation · July 6, 2021
Multiple sodium glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have been shown to impart significant cardiovascular and kidney benefits, but are underused in clinical practice. Both SGLT-2i and GLP-1RA ...
Full textLink to itemCite
Journal ArticleDiabetes Care · April 2021
OBJECTIVE: Obesity and metabolic syndrome are associated with major adverse cardiovascular events (MACE). However, whether distinct metabolic phenotypes differ in risk for coronary artery disease (CAD) and MACE is unknown. We sought to determine the associ ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · January 19, 2021
Background Evidence-based therapies are generally underused for cardiovascular risk reduction; however, less is known about contemporary patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Methods and Results Pharmacy and med ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2021
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic brought about abrupt changes in the way health care is delivered, and the impact of transitioning outpatient clinic visits to telehealth visits on processes of care and outcomes is unclear. METHO ...
Full textLink to itemCite
Journal ArticlePLoS One · 2021
Obesity is an epidemic internationally. While weight loss interventions are efficacious, they are compounded by heterogeneity with regards to clinically relevant metabolic responses. Thus, we sought to identify metabolic biomarkers that are associated with ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · December 15, 2020
Background Coronary artery disease (CAD) is increasing among young adults. We aimed to describe the cardiovascular risk factors and long-term prognosis of premature CAD. Methods and Results Using the Duke Databank for Cardiovascular Disease, we evaluated 3 ...
Full textLink to itemCite
Journal ArticleSci Rep · December 7, 2020
We sought to determine if novel plasma biomarkers improve traditionally defined metabolic health (MH) in predicting risk of cardiovascular disease (CVD) events irrespective of weight. Poor MH was defined in CATHGEN biorepository participants (n > 9300), a ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · October 1, 2020
Triglyceride (TG) levels encompass several lipoproteins that have been implicated in atherogenic pathways. Whether TG levels independently associate with cardiovascular disease both overall and, in particular among patients with established coronary artery ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · July 15, 2020
Hyperuricemia and gout are common in patients with heart failure (HF) and are associated with poor outcomes. Data describing hyperuricemia and gout in patients with HF with preserved ejection fraction (HFpEF) are limited. We used data from the Duke Univers ...
Full textLink to itemCite
Journal ArticleInternational Journal of Applied Geospatial Research · July 1, 2020
In urbanizing India, walkability and outdoor physical activities are essential for a healthy lifestyle. Urban roads need to be assessed for walkability, and public parks need to be assessed as spaces for physical activities. Not many studies have looked at ...
Full textCite
Journal ArticleBMC Pediatr · June 26, 2020
BACKGROUND: The prevalence of child and adolescent obesity and severe obesity continues to increase despite decades of policy and research aimed at prevention. Obesity strongly predicts cardiovascular and metabolic disease risk; both begin in childhood. Ch ...
Full textLink to itemCite
Journal ArticleAm J Prev Med · June 2020
INTRODUCTION: Both medication and surgical interventions can be used to treat obesity, yet their use and effectiveness in routine clinical practice are not clear. This study sought to characterize the prevalence and management of patients with obesity with ...
Full textLink to itemCite
Journal ArticleAm Heart J · June 2020
BACKGROUND: The adoption of 2 classes of new diabetes medications, glucagon-like peptide 1 receptor agonists (GLP1RA) and sodium-glucose co-transporter-2 inhibitors (SGLT2i), has been slow in the United States despite their cardiovascular benefits in addit ...
Full textLink to itemCite
Journal ArticleLancet · May 2, 2020
BACKGROUND: Catheter-based renal denervation has significantly reduced blood pressure in previous studies. Following a positive pilot trial, the SPYRAL HTN-OFF MED (SPYRAL Pivotal) trial was designed to assess the efficacy of renal denervation in the absen ...
Full textLink to itemCite
Journal ArticleCirc Heart Fail · April 2020
BACKGROUND: Palliative care improves quality of life in patients with heart failure. Whether men and women with heart failure derive similar benefit from palliative care interventions remains unknown. METHODS: In a secondary analysis of the PAL-HF trial (P ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Imaging · April 2020
BACKGROUND: Inconclusive noninvasive tests complicate the care of patients with suspected coronary artery disease, but their prevalence and impact on management, outcomes, and costs are not well described. METHODS: PROMISE (Prospective Multicenter Imaging ...
Full textLink to itemCite
Journal ArticleCirculation · March 10, 2020
Responding to concerns about the potential for increased risk of adverse cardiovascular outcomes, specifically myocardial infarction, associated with certain glucose-lowering therapies, the US Food and Drug Administration and the Committee for Medicinal Pr ...
Full textLink to itemCite
Journal ArticleJ Am Geriatr Soc · February 2020
OBJECTIVES: To investigate racial differences in elevated C-reactive protein (CRP) and the potential factors contributing to these differences in US older men and women. DESIGN: Nationally representative cohort study. SETTING: Health and Retirement Study, ...
Full textLink to itemCite
Journal ArticleHeart · February 2020
OBJECTIVES: To test the relationship between increasing severity of obesity, calculated risk and observed outcomes. METHODS: Patients with symptoms suggestive of coronary artery disease (CAD) (n=10 003) were stratified according to body mass index (BMI). W ...
Full textLink to itemCite
Journal ArticleDiabetes Care · February 2020
OBJECTIVE: To compare medical resource use, costs, and health utilities for 14,752 patients with type 2 diabetes who were randomized to once-weekly exenatide (EQW) or placebo in addition to usual diabetes care in the Exenatide Study of Cardiovascular Event ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2020
BACKGROUND: Obesity is a risk factor for type 2 diabetes (T2D) and cardiovascular disease (CVD). Whether obesity affects outcomes among those with T2D and atherosclerotic CVD (ASCVD) remains uncertain. Our objective was to investigate the relationship betw ...
Full textLink to itemCite
Journal ArticleJ Clin Lipidol · 2020
BACKGROUND: Elevated triglycerides (TGs) are associated with increased risk of cardiovascular disease (CVD), but the best way to both measure TGs and assess TG-related risk remains unknown. OBJECTIVE: The objective of the study was to evaluate the associat ...
Full textLink to itemCite
Journal ArticleJ Am Med Inform Assoc · December 1, 2019
OBJECTIVE: Electronic health records (EHR) data have become a central data source for clinical research. One concern for using EHR data is that the process through which individuals engage with the health system, and find themselves within EHR data, can be ...
Full textLink to itemCite
Journal ArticleAm Heart J · December 2019
International differences in management/outcomes among patients with type 2 diabetes and heart failure (HF) are not well characterized. We sought to evaluate geographic variation in treatment and outcomes among these patients. METHODS AND RESULTS: Among 14 ...
Full textOpen AccessLink to itemCite
Journal ArticleCirc Cardiovasc Interv · December 2019
BACKGROUND: Recent trials have identified anti-diabetes mellitus agents that lower major adverse cardiovascular event (MACE) rates, although some increase rates of lower-extremity amputation (LEA). Patients with peripheral artery disease (PAD) have greater ...
Full textLink to itemCite
Journal ArticleCirculation · November 12, 2019
BACKGROUND: Once-weekly exenatide (EQW) had a neutral effect on hospitalization for heart failure (HHF) in the EXSCEL study (Exenatide Study of Cardiovascular Event Lowering), with no differential treatment effect on major adverse cardiac events by baselin ...
Full textLink to itemCite
Journal ArticleClin Cardiol · November 2019
Evidence-based therapy that target hyperlipidemia, hypertension, smoking cessation, and weight loss have demonstrated significant benefits in reducing cardiovascular risks and related events. Although the benefit of intensively lowering blood glucose is un ...
Full textLink to itemCite
Journal ArticleEndocr Pract · May 2019
Objective: This study evaluated whether there is a difference in the proportion of patients with type 2 diabetes who achieve a hemoglobin A1c (HbA1c) <7% within one year following treatment by an endocrinologist or primary care physician (PCP). Methods: We ...
Full textLink to itemCite
Journal ArticleJ Am Med Inform Assoc · May 1, 2019
OBJECTIVE: Participants enrolled into randomized controlled trials (RCTs) often do not reflect real-world populations. Previous research in how best to transport RCT results to target populations has focused on weighting RCT data to look like the target da ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · March 5, 2019
BACKGROUND: The optimal noninvasive test (NIT) for patients with diabetes and stable symptoms of coronary artery disease (CAD) is unknown. OBJECTIVES: The purpose of this study was to assess whether a diagnostic strategy based on coronary computed tomograp ...
Full textLink to itemCite
Journal ArticleObstet Gynecol · March 2019
Cardiovascular disease (CVD) remains the leading cause of mortality for women, and only a small percentage of women have optimally managed risk factors. One of the strongest risk factors for CVD is an increased lipid level. Many women seek primary care fro ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2019
BACKGROUND: Although sex differences exist in the management of acute coronary syndromes, less is known about the management and outcomes of women and men with suspected coronary artery disease being evaluated with noninvasive testing (NIT). METHODS: We in ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Comput Tomogr · 2019
BACKGROUND: Obesity is a risk factor for coronary artery disease (CAD), but adiposity may mimic symptoms of CAD and reduce the accuracy of diagnostic testing. METHODS: Patients from the PROMISE trial (n = 8889) were classified according to body mass index ...
Full textLink to itemCite
Journal ArticleProg Cardiovasc Dis · 2019
Cardiovascular disease (CVD) is the most common cause of morbidity and mortality for patients with diabetes mellitus (DM). Although the burden of atherosclerotic CVD (ASCVD) is well documented, heart failure (HF) has been an under-appreciated CVD complicat ...
Full textLink to itemCite
Journal ArticleAm Heart J · December 2018
BACKGROUND: Patients with nonobstructive coronary artery disease (CAD) have worse outcomes compared with those without CAD; however, few studies have compared the intermediate- and long-term impact of CAD severity as a function of patient sex. METHODS: We ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · October 2, 2018
Background In the EXSCEL (Exenatide Study of Cardiovascular Event Lowering), exenatide once-weekly resulted in a nonsignificant reduction in major adverse cardiovascular events ( MACEs ) and a nominal 14% reduction in all-cause mortality in 14 752 patients ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Heart J · October 2018
IMPORTANCE: The extent to which levels of high-sensitivity C-reactive protein (hs-CRP), a known marker of increased cardiovascular risk, are elevated and are associated with standard cardiovascular risk factors in patients with a history of myocardial infa ...
Full textLink to itemCite
Journal ArticleJAMA Netw Open · September 7, 2018
IMPORTANCE: Data from electronic health records (EHRs) are increasingly used for risk prediction. However, EHRs do not reliably collect sociodemographic and neighborhood information, which has been shown to be associated with health. The added contribution ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · August 21, 2018
Background Epidemiological studies demonstrating a relationship between gout and cardiovascular disease are older and predate modern cardiovascular preventive therapy. We assessed the contemporary association between gout and cardiovascular disease in pati ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · July 3, 2018
This review describes trends in the burden of cardiovascular diseases (CVDs) and risk factors in India compared with the United States; provides potential explanations for these differences; and describes strategies to improve cardiovascular health behavio ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · June 30, 2018
BACKGROUND: There is limited information about the long-term survival of older patients after myocardial infarction (MI). METHODS AND RESULTS: CRUSADE (Can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implement ...
Full textLink to itemCite
Journal ArticleLancet Diabetes Endocrinol · February 2018
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular efficacy were varied. We ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · October 31, 2017
BACKGROUND: The impact of diabetes mellitus on the clinical presentation and noninvasive test (NIT) results among stable outpatients presenting with symptoms suggestive of coronary artery disease (CAD) has not been well described. METHODS AND RESULTS: The ...
Full textLink to itemCite
Journal ArticleN Engl J Med · September 28, 2017
BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, ...
Full textOpen AccessLink to itemCite
Journal ArticleCirculation · September 26, 2017
BACKGROUND: Intensive risk factor modification significantly improves outcomes for patients with diabetes mellitus and cardiovascular disease. However, the degree to which secondary prevention treatment goals are achieved in international clinical practice ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · September 1, 2017
This population-based study uses the Acute Coronary Treatment and Intervention Outcomes Network Registry to evaluate the prevalence of smoking cessation medication use among patients following myocardial infarction. ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2017
BACKGROUND: EXSCEL is a randomized, double-blind, placebo-controlled trial examining the effect of exenatide once-weekly (EQW) versus placebo on time to the primary composite outcome (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2017
BACKGROUND: Studies have suggested a relationship between higher baseline serum uric acid (sUA) levels and an elevated risk of subsequent ischemic cardiovascular outcomes among acute coronary syndrome (ACS) patients; this relationship may be modified by a ...
Full textLink to itemCite
Journal ArticleJAMA · April 18, 2017
IMPORTANCE: There are important differences among guideline recommendations for using statin therapy in primary prevention. New recommendations from the US Preventive Services Task Force (USPSTF) emphasize therapy based on the presence of 1 or more cardiov ...
Full textLink to itemCite
Journal ArticleNat Rev Cardiol · August 2016
Evidence of sex-related disparities in the care and outcomes of patients with acute coronary syndrome (ACS) emerged >30 years ago, and yet the mechanisms behind these sex-specific differences remain unclear. In this Review, we discuss the current literatur ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · June 7, 2016
BACKGROUND: Although risk stratification is an important goal of cardiac noninvasive tests (NITs), few contemporary data exist on the prognostic value of different NITs according to patient sex. OBJECTIVES: The goal of this study was to compare the results ...
Full textLink to itemCite
Journal ArticleJACC Cardiovasc Imaging · April 2016
OBJECTIVES: The aim of this study was to determine whether presentation, risk assessment, testing choices, and results differ by sex in stable symptomatic outpatients with suspected coronary artery disease (CAD). BACKGROUND: Although established CAD presen ...
Full textLink to itemCite
Journal ArticlePLoS One · 2013
BACKGROUND: Studies from high-income countries have shown that women receive less aggressive diagnostics and treatment than men in acute coronary syndromes (ACS), though their short-term mortality does not appear to differ from men. Data on gender differen ...
Full textLink to itemCite
Book · 2013
Chronic diseases are increasingly becoming a health burden in lower- and middle-income countries, putting pressure on public health efforts to scale up interventions. This article reviews current efforts in interventions on a population and individual leve ...
Full textLink to itemCite